Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...

After delaying its review, the FDA has rejected Aldeyra Therapeutics’ experimental dry eye disease treatment for the third time. | After delaying its review, the FDA has rejected Aldeyra Therapeutics’ ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

Aldeyra Therapeutics Inc. ALDX shares are tumbling on Tuesday following the U.S. Food and Drug Administration (FDA) update.

More than 360 million people around the world suffer from dry eye disease, which is characterized by chronically red, scratchy or irritated eyes. blackday - stock.adobe.com Dry eye disease is no ...

Aldeyra plans to request a Type A meeting and currently does not intend further clinical trials, asserting rapid-onset activity within minutes versus existing therapies requiring weeks to months.

Adults with a deficiency of vitamin D are at increased risk for developing dry eye disease than those without low levels of the nutrient, a study finds.

Laughing may be as effective as drops for treating dry eyes, according to a new study. Laughter should be the “go to” treatment for relieving symptoms of the common condition, say Chinese scientists.

Add Yahoo as a preferred source to see more of our stories on Google. More than half of people in the U.S. and Europe struggle with dry eyes, but only a small percentage of sufferers seek treatment ...

MFDS IND approval enables a multicenter, randomized, double-blind, vehicle-controlled phase 2 study in ~150 DED patients, randomized 1:1:1 to two dosing arms versus control over 12 weeks. Prior phase ...